Antigen-Specific T Cell Production via iPS Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing antigen-specific T cells, particularly CD8 single-positive cells, face challenges in maintaining high proliferation capability and accurate TCR gene rearrangement patterns, leading to insufficient therapeutic efficacy in cellular adoptive immunotherapy.
Innovation Solution
A method involving the differentiation of induced pluripotent stem cells (iPS cells) from human T cells into CD4/CD8 double-negative cells, followed by stimulation of the T cell receptor and differentiation into CD8 or CD4 single-positive cells, using anti-CD3 antibody and IL-7, to enhance the frequency of cells with the same TCR gene rearrangement pattern as the original cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If T cells are massively proliferated ex vivo for cellular adoptive immunotherapy, then the quantity of T cells is increased, but the T cell function is lost and therapeutic efficacy remains insufficient
Solution Approach 1:
The patent segments the T cell production process into distinct stages: generating antigen-specific precursor cells from patient cells, expanding these cells under controlled conditions to maintain functionality, and then differentiating them into therapeutic T cell products. This segmentation allows each stage to be optimized independently, preserving T cell function while achieving massive proliferation.
Solution Approach 2:
The patent applies preliminary action by pre-activating and expanding antigen-specific T cell precursors under optimized culture conditions before final differentiation and transplantation. This preliminary expansion phase is designed to maintain T cell receptivity and functionality while achieving the necessary cell quantities for effective therapy.
2Ease of manufacture
If conventional methods are used to induce antigen specificity in non-specific T cells, then T cell production is simplified, but mispairing TCR is made and antigen specificity is compromised
Solution Approach 1:
The patent uses antigen-presenting cells or antigen-specific stimulation as an intermediary to induce proper TCR signaling and gene rearrangement. This intermediary approach ensures that T cells develop correct antigen specificity through physiological TCR engagement rather than direct genetic manipulation, maintaining both manufacturing feasibility and TCR precision.
Solution Approach 2:
The patent employs parameter changes in culture conditions, cytokine concentrations, and stimulation protocols to guide proper TCR gene rearrangement and antigen specificity development. By optimizing these parameters, the process achieves both ease of manufacture and high precision in TCR pairing without mispairing events.
3Reliability
If T cells are exposed to long-term latent virus infections or tumors/self-antigens, then antigen recognition experience is gained, but T cell exhaustion occurs and antigen responsive T cell pool is lost
Solution Approach 1:
The patent applies preliminary action by expanding and activating antigen-specific T cell precursors ex vivo before transplantation, rather than relying on in vivo expansion that leads to exhaustion. This preliminary expansion under optimized conditions preserves T cell potency and prevents exhaustion while ensuring sufficient cell numbers for effective therapy.
Solution Approach 2:
The patent essentially creates a copy of the desired T cell response by isolating and expanding specific antigen-reactive clones ex vivo, then transplanting these refreshed copies back to the patient. This copying approach bypasses the exhaustion that occurs during prolonged in vivo antigen exposure while maintaining antigen recognition capability.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
[Problem] To obtain a very high frequency of T cells having the same TCR gene reconstitution pattern as the original human T cells in CD8 single-positive cells or CD4 single-positive cells obtained by redifferentiation from human T cells having antigen specificity via iPS cells. [Solution] A method for producing human CD8 single-positive cells or CD4 single-positive cells having antigen specificity, wherein the method comprises a step for differentiating to CD4/CD8 double-negative cells iPS cells induced from human T cells, a step for stimulating the T cell receptor of the CD4/CD8 double-negative cells, and a step for differentiating to CD8 single-positive or CD4 single-positive cells the CD4/CD8 double-negative cells whose T-cell receptor has been stimulated.